A logical network-based drug-screening platform for Alzheimer's disease representing pathological features of human brain organoids

Developing effective drugs for Alzheimer's disease (AD), the most common cause of dementia, has been difficult because of complicated pathogenesis. Here, we report an efficient, network-based drug-screening platform developed by integrating mathematical modeling and the pathological features of AD with human iPSC-derived cerebral organoids (iCOs), including CRISPR-Cas9-edited isogenic lines. We use 1300 organoids from 11 participants to build a high-content screening (HCS) system and test blood-brain barrierpermeable FDA-approved drugs. Our study provides a strategy for precision medicine through the convergence of mathematical modeling and a miniature pathological brain model using iCOs.

Automated summary

This study reports an efficient drug screening platform integrating mathematical modeling and the pathological features of AD with human iPSC-derived cerebral organoids. By using 1300 organoids from 11 participants, they built a high-content screening system and tested FDA-approved drugs that can permeate the blood-brain barrier. The study provides a strategy for precision medicine through the convergence of mathematical modeling and a miniature pathological brain model using iCOs.